With increasing time since diagnosis, only the severe infections continued to cause symptoms.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
However, two thirds of US adults say it will not be safe for gatherings of 10 or more until midsummer.
In a study yesterday in Morbidity and Mortality Weekly Report (MMWR), researchers describe a COVID-19 super-spreading event at a Washington state choir practice in March, which was attended by a symptomatic index patient and produced an attack rate of 53.3% to 86.7%.
Researchers says there's no question the novel virus originated in nature.
Fauci warns senators that states risk new and worsening COVID-19 outbreaks if they move too fast.
Russia reports almost 11,000 new cases, part of an ongoing surge mainly centered in Moscow.
Vaccine development hinges on "unprecedented" and transparent efforts, top US experts say.
A retrospective study of COVID-19 patients in New York City hospitals found that treatment with the antimalaria drug hydroxychloroquine, the antibiotic azithromycin, or both was not significantly associated with differences in in-hospital mortality compared with patients who received neither drug.
Some 5,000 COVID-19 deaths in New York City might not have been counted, a new report says.
The WHO also warns that COVID-19 disruptions could hurt the battle against HIV.
A phase 2 trial has shown that a 2-week course of triple antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin is safe and better at shortening COVID-19 viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness if started within 7 days of symptom onset.
